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Abstract
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Background—Cardiovascular disease (CVD) is highly prevalent among children with chronic
kidney disease (CKD). Cystatin C is an established marker of kidney function and an emerging
biomarker for CVD events. We quantified the relationship between cystatin C and cardiac
structure and function over time among children with CKD and assessed whether cystatin C and
diastolic function retained an association after accounting for kidney function.
Study Design—Prospective cohort study.
Setting & Participants—678 children and adolescents with mild-moderate CKD enrolled in the
Chronic Kidney Disease in Children (CKiD) study with 1228 echocardiographically obtained
cardiac structure and function measures.
Predictor—Serum cystatin C (mg/L) measured annually.
Outcomes—Cardiac structure (left ventricular mass index [g/m2.7]) and cardiac function
(shortening fraction; E/A, E′/A′, E/E′ ratios) measured every other year.
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Measurements—Demographics and anthropometrics, measured glomerular filtration rate
(mGFR), heart rate, blood pressure, hemoglobin z score, serum albumin and calcium-phosphorus
product.
Results—Independent of time, each 1-mg/L increase in cystatin C was independently associated
with a concurrent 7.7% (95% CI, 5.3%–10.0%) increase in left ventricular mass index, a −4.7%
(95% CI, −7.0% to −2.4%) change in E/A, a −6.6% (95% CI, −9.0% to −4.2%) change in E′/A′,
and a 2.5% (95% CI, 0.3–4.7) increase in E/E′ ratio. mGFR was also independently associated
with E′/A′. When cystatin C and mGFR were included in the same model, cystatin C remained
independently associated with E′/A′ while mGFR was not.
Limitations—24% of the cohort was missing data on outcomes of interest or measurements;
study population only includes children and adolescents with mild to moderate CKD.
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Conclusion—In this study of children and adolescents with mild-moderate CKD, cystatin C was
independently associated with cardiac structure and diastolic function. Cystatin C remained able to
predict diastolic function decline via E′/A′ even after adjusting for mGFR, suggesting that
cystatin C may have an independent role in CVD risk stratification among children and
adolescents with CKD.
Index Words
biomarker; cardiovascular disease (CVD); left ventricular hypertrophy (LVH); left ventricular
mass (LVM); pediatrics; children; adolescents; systolic function; cystatin C; chronic kidney
disease (CKD); renal function; echocardiograph; cardiac structure; cardiac function
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Sudden cardiac death remains the most common cause of mortality among children with
chronic kidney disease (CKD)(1). Children with CKD manifest a multitude of
cardiovascular disease (CVD) risk factors, and show early signs of heart disease including
dilated cardiomyopathy and left ventricular hypertrophy (LVH). The progression of these
abnormalities to cardiac death is thought to explain the markedly decreased lifespans of
children with advanced CKD(1). While the increased CVD risk in youth with CKD has been
well established(2, 3), the morbidity and mortality related to CVD has nevertheless
increased over time(4). Identifying new biomarkers or clinical characteristics that could
more easily identify those at increased CVD risk would help tailor treatment efforts.
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Diastolic dysfunction is one of the earliest signs of cardiac disease among children with
CKD(5) and it progresses as CKD advances(5, 6). Despite this, serum creatinine has not
been shown to be a reliable biomarker of diastolic dysfunction(5, 7). Cystatin C, an
endogenous proteinase inhibitor widely utilized as a surrogate marker of kidney function, is
an emerging biomarker for CVD events. Cystatin C is associated with cardiac geometry,
cardiac remodeling and CVD outcomes in adults(8–11). In this study, we aimed to quantify
the independent relationship between cystatin C and both cardiac structure and function over
time among children and adolescents with mild to moderate CKD. We also sought to
determine how well other measures of kidney function predict diastolic function, and if any
independent relationship between cystatin C and diastolic function existed after accounting
for directly measured kidney function.
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Methods
Study Population
As of December 2015, 891 children and adolescents (586 in April 2005–August 2009 and
305 between February 2011 and March 2014) with mild to moderate CKD were enrolled in
the Chronic Kidney Disease in Children (CKiD) Study, a multicenter, prospective cohort
study conducted at 49 pediatric nephrology centers across North America. The study design
and conduct were approved by an observational study monitoring board appointed by the
National Institute of Diabetes and Digestive and Kidney Diseases and by the internal review
boards of each participating center. Data approval numbers are as follows: data coordinating
center, H.34.03.09.05.A2; East Coast Clinical Coordinating Center, 10-007880; and
Midwest Clinical Coordinating Center, 11120124. Each participating family provided
informed consent.

Author Manuscript

Study participants attended annual follow-up visits after their initial baseline visit. Children
and adolescents were included in our analyses if they had echocardiography data from one
or more visits and complete data on the exposure of interest and all covariates. There were
1,401 visits, across 733 participants, with full echocardiography data that had occurred by
December 2015. At 173 of these visits, the exposure of interest or at least one covariate was
missing, leaving 1,228 visits from 678 children and adolescents (median follow-up, 3.0
years) in our primary analysis. The 678 participants contributed one to four visits to the
analysis (334, one visit; 188, two visits; 106, three visits; and 50, four visits [Figure 1]).
Echocardiography
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At even-numbered annual CKiD visits (or once every two years) participants undergo local
standardized protocol echocardiography. Images are read centrally by a study cardiologist
where measurements are taken in triplicate and averaged. Left ventricular mass (LVM) is
obtained by American Society of Echocardiography criteria(12, 13) using 2D M-mode, and
the LVM index (LVMi) is calculated as LVM/height2.7 where LVM is in grams and height is
in meters(12, 14). To assess systolic function, shortening fraction (SF) was obtained: [(LV
end-diastolic diameter – LV end-systolic diameter)/LV end-diastolic diameter]. Pulsed-wave
tissue Doppler in the apical view is used to obtain the maximal early filling (E-wave) and
late diastolic filling (A-wave) velocities, the early diastolic annular velocity (E′) and the late
diastolic annular velocity (A′)(15). These measurements are then used to obtain the
measures of diastolic function described below.
Primary Outcomes
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The LVMi was used to determine cardiac structure, with values at or greater than the age-/
sex-specific 95th percentile indicative of LVH(16). Systolic function was ascertained by SF.
Values <25% indicate abnormally low SF. Diastolic function was assessed via three ratios:
E/A ratio (early-to-atrial LV filling ratio), E′/A′ ratio (early-to-late septal mitral annular
peak velocity) and E/E′ ratio (estimate of LV filling pressure). Normal E/A and E′/A′
ratios are >1.0; lower values denote stiffer ventricular walls and diminished ability for
adequate LV relaxation and fill. The E/E′ ratio is an estimate of LV filling pressures, and
normal values are <8.0(15); higher values indicate worse LV compliance.
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Cystatin C was measured at each annual visit. Serum specimens were analyzed by
standardized methods to produce measurements in mg/L(17). The cystatin C value taken at
the time of echocardiography was used in the analyses.
Covariates
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The following variables were included in all multivariable analyses: baseline age, sex, race;
average age-/sex-specific body mass index z score from current (visit with
echocardiography) and previous visit (visit immediately prior to echocardiography); average
age-/sex-/height-specific systolic and diastolic blood pressure z scores from current and
previous visit (measured via manual auscultation); and years with CKD at the time of
echocardiography. Multivariable models for cardiac structure and diastolic function were
additionally adjusted for the average serum calcium-phosphorous product from current and
previous visit. The model for systolic function was further adjusted for average heart rate
from 24-hour ambulatory blood pressure monitoring (ABPM); average race-/age-/sexspecific hemoglobin z score from current and previous visit; average serum albumin (g/dL)
from current and previous visit, and β-blocker, angiotensin-converting enzyme inhibitor or
angiotensin II receptor blocker use (not used at prior nor current visit versus use at prior visit
only versus use at current visit only versus use at both visits). Due to incomplete ABPM
measurements, the model for systolic function only includes the 953 visits from 581
participants with a valid mean heart rate from 24-hour ABPM.
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In our second set of analyses, we determined the effect other time-varying measures of
kidney function had on both E′/A′ and E/E′ in comparison to cystatin C. These kidney
function measures included serum creatinine (Scr)-based estimated GFR, or eGFRcr =
(0.413 × height in cm)/Scr; serum urea nitrogen (SUN)-, Scr-, and cystatin C-based eGFR,
or eGFRSUN-cr-cys = 39.8 × (height in m/Scr)0.456 × (1.8/Cystatin C)0.418× (30/SUN)0.079 ×
1.076 (if male) × (height in m/1.4)0.179, serum creatinine, GFR measured by the plasma
disappearance of iohexol [mGFR]).
Statistical Analyses
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We conducted longitudinal analyses using the echocardiogram data from visits two, four, six
and eight. Visit was treated as a categorical variable. Linear mixed models were used to
determine the longitudinal association of cystatin C with cardiac structure (LVMi), systolic
function (SF), and diastolic function (E/A, E′/A′ and E/E′ ratios). These models have the
advantage that complete data are required only for a given visit, rather than for all visits for a
given subject. Model parameters were estimated by the method of maximum likelihood,
which produces unbiased estimates when data are missing at random. To account for the
correlation among repeated observations on a given subject, all mixed models were adjusted
for repeated visits with a random subject effect. Random subject effects were chosen
because they are plausible as a reflection of individual characteristics of members of the
population from which the study subjects were sampled. Furthermore, this approach is more
parsimonious than treating ‘subject’ as a fixed effect, which is an approach that produces
models with large numbers of parameters. Likelihood ratio statistics revealed no significant
effects of cystatin C by visit, so for simplicity we present the main effects models without
Am J Kidney Dis. Author manuscript; available in PMC 2018 February 01.
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cystatin C by visit interaction terms. All outcomes were log transformed to achieve normally
distributed errors with constant variance; effects in this case are expressed multiplicatively
as percent changes. Partial residual plots were used to graphically depict the relationship
between cystatin C and the E/A, E′/A′ and E/E′ ratios after adjustment. A partial residual
for a given predictor variable in a regression model is obtained by taking the raw residual
from the model (observed minus predicted; in these mixed models, the raw residual included
adjustment for the individual values of the random intercept using the best linear unbiased
predictor, thus adjusting for repeated measurements of individual subjects), and adding back
the product of the estimated regression coefficient and the value of the predictor variable
(i.e., cystatin C) for each subject. Plots of the partial residuals versus the values of the
independent variable are useful in visualizing the estimated effect of the predictor variable in
a multivariable model.
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To evaluate how other measures of kidney function predict diastolic function, we chose E′/A
′ and E/E′ as our outcomes, as these measures are more widely used for assessment of
diastolic function. We then investigated the relationship of the following measures of kidney
function with diastolic function in separate models, adjusting for the same covariates:
eGFRcr; eGFRSUN-cr-cys; serum creatinine (with height additionally added to this model);
and mGFR. Lastly, our final model included both mGFR and cystatin C to determine the
longitudinal relationship each had with diastolic function, adjusting for the other, as well as
eGFRcr and cystatin C in a separate model. Due to missing mGFR measurements, this
second set of analyses includes 1,163 visits from 655 children and adolescents. A two-sided
p-value <0.05 was considered statistically significant. Statistical analyses were conducted
using SAS 9.4 (SAS Institute Inc, Cary NC, USA).
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Results
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Characteristics of the 678 children and adolescents from the CKiD Study included in our
analyses at the first visit with echocardiography and cystatin C measured concurrently are
presented in Table 1. Participants included in our analyses did not differ substantially from
those excluded from the analysis at visit one (Table S1, available as online supplementary
material). Twelve percent had LVH. Most had normal systolic function; only 1.5% had a SF
<25%. The diastolic function values were largely in the normal range (1st quartiles of E/A
and E′/A′ ratios, >1; median E/E′ ratio, <8). Over time, the prevalence of SF <25%
increased to 2.1%. The LVH prevalence and the E/A, E′/A′, E/E′ ratios remained similar.
The median values of cystatin C, serum creatinine, and mGFR were 1.4 mg/L, 1.2 mg/dL,
and 51.9 mL/min/1.73 m2, respectively. The median of the age-/sex-/height-specific systolic
and diastolic blood pressure z scores were 0.2 and 0.4, respectively. Sixty-five percent of
participants reported use of β-blockers, angiotensin-converting enzyme inhibitors, or
angiotensin II receptor blocker medications at either their prior or current visit. Seven
percent reported corticosteroid use.
Cystatin C was independently associated with increasing LVMi over time using 1,228 visit
pairs contributed by 678 participants: each 1-mg/L increase in cystatin C was associated
with a 7.7% (95% confidence interval [CI], 5.3%–10.0%) increase in LVMi (Table 2).
Cystatin C was not associated with systolic function, but was independently associated with

Am J Kidney Dis. Author manuscript; available in PMC 2018 February 01.

Brady et al.

Page 6

Author Manuscript

decreased E/A and E′/A′ ratios, and increased E/E′ ratio. Specifically, each 1-mg/L
increase in cystatin C was associated with a −4.7% (95% CI, −7.0% to −2.4%) change in the
E/A ratio and a −6.6% (95% CI, −9.0% to −4.2%) change in the E′/A′ ratio. The same
increase in cystatin C was also independently associated with a 2.5% (95% CI, 0.3%–4.7%)
increase in the E/E′ ratio. Figures 2–4 show the relationship between cystatin C and E/A
ratio, E′/A′ ratio, and E/E′ ratio after adjusting for all covariates shown in Table 2. The
slope of each regression line corresponds to the percentage change shown in Table 2.
Furthermore, there is substantial heterogeneity in each outcome for a given value of cystatin
C.
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Author Manuscript

We restricted our second set of analyses to 1163 visits with mGFR measurements and
diastolic function measured concurrently to quantify the independent association between
other markers of kidney function and diastolic function (Table 3). Of all the markers of
kidney function, cystatin C was associated with the greatest percent decline in the E′/A′
ratio: a 1-mg/L increase in cystatin C was associated with a −6.0% (95% CI, −8.4% to
−3.5%) change in E′/A′ ratio. In comparison, a −25–ml/min/1.73 m2 change in mGFR was
associated with a −3.7% (95% CI, −5.8% to −1.7%) change in E′/A′ ratio. When cystatin C
and mGFR were included in the model together, the association of cystatin C with diastolic
function was slightly attenuated (−5.3% [95% CI, −8.6% to −1.8%] change) but there was
no longer a significant association of mGFR with diastolic function (−0.9% [95% CI, −3.7%
to 1.9%] change). When cystatin C and the eGFRcr were included in the same model, the
inferences are nearly identical, with slightly stronger associations (Model 7, Table 3).
Cystatin C was associated with an increase in the E/E′ ratio but to a much lesser degree
(2.4% [95% CI, 0.2%–4.6%] increase) than the change seen with the E′/A′ ratio. Neither
cystatin C nor mGFR were associated with the E/E′ ratio when both were included in the
model.

Discussion
In this longitudinal, observational cohort study of children and adolescents with mild to
moderate CKD, greater cystatin C was independently associated with increasing LVMi and
worsening diastolic function. This serum marker, more commonly considered a surrogate
marker of kidney function, was also able to predict decline in diastolic function as measured
by E′/A′ ratio even after adjusting for kidney function as assessed by the plasma
disappearance of iohexol. This suggests that cystatin C may have an independent role in
CVD risk stratification among children and adolescents with CKD, a particularly vulnerable
group.
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Cystatin C has several characteristics that make it an ideal biomarker for the estimation of
kidney function. Specifically, it is steadily produced by all nucleated cells, freely filtered at
the glomerulus, entirely reabsorbed and catabolized by the proximal tubules, and not renally
secreted(9). Cystatin C is also biologically active as a cysteine protease inhibitor. Cysteine
proteases such as cathepsins promote cardiovascular extracellular matrix degradation. When
cathepsin activity is increased, cystatin C expression is similarly increased to counterbalance
this activity. When there is an imbalance between this proteolytic activity and cystatin C,
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myocardial remodeling occurs. This leads to alterations in left ventricular size, shape and
function(9).
This biologic activity has prompted animal and human research into possible associations
between cystatin C and CVD measures and outcomes. Several studies in adults have indeed
described such an association among individuals with and without kidney disease(8, 9, 11).
Because young people are free of many of the co-morbidities that can confound observed
associations between cystatin C and CVD outcomes, studying this population is ideal,
particularly when trying to tease out any contribution decreased kidney function may have
on this relationship.
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Prior studies in adults have led to consensus statements defining CKD as an independent risk
factor for coronary heart disease(18, 19) making CVD risk prediction a priority in this
population. In 2011, a large meta-analysis demonstrated that the hazard ratio for CVD
mortality increased with decreasing kidney function(20). Even among children, CKD is
considered a significant CVD risk factor. In fact, children with CKD are considered to be in
the highest category of CVD risk, grouped along with children who are heart transplant
recipients and who have diabetes, among others(21).
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Clinically, at-risk children are screened for intermediate outcomes such as LVH to assess
their CVD risk. In addition, diastolic function is also determined via echocardiography and
can add to an individual’s overall CVD risk assessment. Diastolic dysfunction is one of the
main precursors to heart failure and CVD events in adults. The abnormal relaxation and
decreased distensibility of the left ventricle that occurs in diastole and characterizes diastolic
dysfunction leads to impaired LV filling. As a result, increased pressure in the left ventricle,
left atrium and pulmonary vasculature can occur. Diastolic dysfunction is often
asymptomatic, but patients with diastolic heart failure may have difficulty tolerating
tachycardia and abrupt changes in blood pressure as these forms of hemodynamic stress can
limit LV filling, impair preload and further limit cardiac relaxation. Early identification of
those at risk for diastolic heart failure, particularly among individuals with CKD who are
more prone to hemodynamic stress, is imperative for early treatment and prevention of CVD
events.
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While the association between CKD and CVD has been established for over a decade,
several studies have called this into question and contending no increased CVD risk among
those with mild to moderate CKD(22, 23). One explanation for these conflicting findings is
that many studies with negative results utilized creatinine-based estimating equations for the
definition of CKD in contrast to mGFR. In individuals with GFR >60 ml/min/1.72m2, these
equations are known to underestimate kidney function(24) and can therefore lead to
misclassification bias.
With the development of more sophisticated cystatin C–based estimating equations, the
association between CKD and CVD has been more strongly established among individuals
with milder CKD. Recent studies also suggest that cystatin C may offer additional
prognostic advantages to CVD risk stratification. Among elderly individuals followed up for
as long as 9 years, cystatin C was a much stronger predictor of CVD events than creatinine
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and was directly associated with all-cause death in a dose-response manner(25). In an
observational study of adults with non-diabetic CKD stages 3–4, cystatin C was found to be
at least as, if not more, strongly associated with CVD mortality than mGFR or
creatinine(26).
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In our study, we show that among children and adolescents with mild to moderate CKD,
cystatin C is an independent predictor of diastolic function. A prior study in adults attributed
the association between cystatin C and CVD morbidity and mortality to the close correlation
of cystatin C with kidney function(26). In fact, the addition of cystatin C to equations
designed to estimate GFR has greatly added to our ability to stage and follow up children
with CKD(27). However, we demonstrate here that increasing levels of cystatin C predicted
diastolic function decline, independent of kidney function. So, while each commonly
utilized method of eGFR among children and adolescents was significantly associated with
diastolic function as ascertained by E′/A′ ratio, cystatin C remained associated even after
controlling for mGFR. Adding cystatin C to the panel of tests used to assess CVD risk could
help risk stratify these young people and facilitate identification and treatment of additional
risk factors.
LVH is a common precursor to diastolic dysfunction and is present in 17%–50% of children
with CKD stages 2–4(27). We also demonstrated that increasing cystatin C was associated
with an increase in LVMi over time. This is similar to findings described from a crosssectional analysis in the Chronic Renal Insufficiency Cohort (CRIC) study: worsening
kidney function as ascertained by cystatin C–based eGFR was strongly associated with
higher LV mass, increased LVH, and abnormal LV geometry(28).
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Systolic dysfunction was rare in our population. This is not surprising, as systolic function is
thought to be relatively preserved in children with CKD, only becoming manifest once
children reach end-stage disease(27). It is possible that we did not see an association
between cystatin C and systolic function because so few participants in our cohort had
dysfunction. This will need to be confirmed in future studies.
Interestingly, cystatin C did not have a significant interaction with time. This suggests that
the relationship of cystatin C with diastolic function is constant—that it does not change
(i.e., become stronger or weaker) with CKD duration. The finding that time did not modify
the relationship between cystatin C and diastolic function lends further support that this
serum marker may have a role in risk stratifying children and adolescents at any point in
their course of kidney disease.
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While we saw a strong independent association of cystatin C with E′/A′ ratio, we did not
see a similar association between cystatin C and E/E′ ratio when mGFR was included in the
multivariable model. This may be because the two ratios are assessing slightly different
aspects of diastolic function: the E′/A′ ratio assesses ventricular filling (lower ratios
indicating a stiffer ventricular wall) and the E′/E ratio assesses ventricular compliance
(greater ratios indicating worsening compliance). Future studies are needed to explore this
further.
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Our study has several limitations. Not all participants had all measures of interest,
particularly when related to the 24-hour ABPM, so we were unable to benefit fully from the
large population in the CKiD study. Interestingly, the median mGFR ascertained at the
baseline visit of those included in our analyses compared to that of those not included
because of missing data were nearly identical (52.3 versus 50.8 ml/min/1.73 m2 [see Table
S1]), which gives some assurance that we did not study a select group of healthier children
and adolescents with respect to their stage of CKD. In addition, our population only
included children and adolescents with mild to moderate CKD, with a relatively narrow
range of GFR. Therefore, we cannot extend our observations to young people with normal
kidney function or more advanced stages of CKD.
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Our study also has several notable strengths. We present longitudinal data from a large,
diverse group of children and adolescents with CKD, free of multiple risk factors
confounding similar studies in adults. As examples, young people are typically free of many
CVD risk factors related to lifestyle (smoking, alcohol use, diabetes) and have not had
extended exposure to other traditional risk factors (dyslipidemia, hypertension, obesity,
kidney failure). Another strength was that we were able to demonstrate a clear association of
an easily obtained biomarker on a measured form of non-fatal CVD, providing an
intermediate end point for targeted intervention. Finally, our data includes mGFR which
allows for more accurate assessment of kidney function.
In summary, we were able to demonstrate that cystatin C independently predicts LVMi and
diastolic function among children and adolescents with CKD. This presents an opportunity
for improved risk stratification and more targeted therapies for children and adolescents with
CKD, a group particularly at risk for CVD morbidity and mortality.
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Figure 1.

Flow chart outlining the number of visits and number of participants contributing data to the
primary and subsequent analyses
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Figure 2. Partial residual plot of adjusted E/A Ratio versus Cystatin C (mg/L)
aAdjusted

for baseline age, gender, African-American race, age-sex specific BMI z score,
age-/sex-/height-specific systolic and diastolic blood pressure z scores, calcium-phosphorus
product, and follow-up time. The outcome variable was log transformed for analysis.
Multiple points for each subject were included in the longitudinal analysis and are included
in the plot, with adjustment for the individual values of the random intercept.
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Figure 3. Partial residual plot of adjusted E′/A′ Ratio versus Cystatin C (mg/L)
aAdjusted

for baseline age, gender, African-American race, age-sex specific BMI z score,
age-/sex-/height-specific systolic and diastolic blood pressure z scores, calcium-phosphorus
product, and follow-up time. The outcome variable was log transformed for analysis.
Multiple points for each subject were included in the longitudinal analysis and are included
in the plot, with adjustment for the individual values of the random intercept.
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Figure 4. Partial residual plot of adjusted E/E′ Ratio versus Cystatin C (mg/L)
aAdjusted

for baseline age, gender, African-American race, age-sex specific BMI z score,
age-/sex-/height-specific systolic and diastolic blood pressure z scores, calcium-phosphorus
product, and follow-up time. The outcome variable was log transformed for analysis.
Multiple points for each subject were included in the longitudinal analysis and are included
in the plot, with adjustment for the individual values of the random intercept.
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51.2 (34.5, 67.7)
51.6 (36.8, 66.2)
9.3 (5.1, 13.5)
12.3 (9.0, 15.9)

eGFRcr a

eGFRSUN-cr-cys b

Length of time with CKD, y

Age, y

82 (74, 89)

51.9 (37.3, 72.4)

mGFR, mL/min/1.73m2

Heart Rate from 24-h ABPMc

1.2 (0.9, 1.7)

Serum Creatinine, mg/dL

16% (109)

1.4 (1.1, 2.0)

Cystatin C, mg/L

African American

7.3 (6.3, 8.6)

E/E′ Ratio

39% (265)

1.9 (1.5, 2.4)

E′/A′ Ratio

Female sex

1.8 (1.5, 2.3)

37% (34%, 41%)

12% (82)

30.7 (25.6, 37.2)

(N=678)

Overall

E/A Ratio

Shortening Fraction, %

LVH

LVMi, g/m2.7

Characteristics

80 (72, 89)

29% (20)

41% (29)

14.2 (9.4, 17.1)

6.2 (2.5, 11.3)

91.9 (81.6, 99.1)

88.5 (75.5, 103.4)

106.3 (100.7, 114.6)

0.7 (0.6, 0.9)

0.8 (0.7, 0.9)

7.2 (5.9, 8.2)

2.0 (1.5, 2.5)

2.0 (1.6, 2.3)

36% (32%, 40%)

7% (5)

28.6 (24.8, 34.8)

(n=70)

≥90

81 (73, 87)

18% (35)

31% (60)
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38% (35%, 41%)

14% (21)
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85 (76, 89)
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Characteristics of 678 CKiD Study participants at first visit with echocardiogram and cystatin C measured concurrently.

83 (74, 90)

12% (12)

35% (35)

13.9 (9.8, 16.1)

11.0 (6.2, 14.8)

25.4 (21.2, 30.1)

23.5 (16.9, 29.2)
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2.7 (2.4, 3.3)
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34.4 (28.7, 40.5)
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0.4 (−0.2, 1.0)

Age-/Sex-/Height-specific Diastolic BP z scored

39.6 (35.2, 44.2)

4.5 (4.2, 4.6)

0.9 (0.1, 1.6)

0.0 (−1.0, 1.1)

14% (10)

34% (24)

57% (40)

6% (4)

3% (2)

0.2 (−0.3, 0.8)

0.0 (−0.8, 0.9)

(n=70)

41.3 (37.6, 45.2)

4.5 (4.3, 4.7)

0.5 (−0.3, 1.2)

0.0 (−1.2, 0.8)

5% (10)

41% (80)

51% (98)

5% (10)

3% (6)

0.3 (−0.2, 0.8)

0.0 (−0.6, 0.7)

(n=194)

60–89

42.3 (37.5, 47.0)

4.4 (4.2, 4.6)

0.5 (−0.2, 1.3)

−0.4 (−1.6, 0.6)

5% (7)

37% (55)

48% (72)

9% (13)

6% (9)

0.4 (−0.1, 1.0)

0.4 (−0.2, 0.8)

(n=149)

45–59

43.5 (40.3, 47.3)

4.3 (4.1, 4.5)

0.3 (−0.5, 1.1)

−1.4 (−2.2, −0.1)

7% (11)

30% (49)

53% (88)

11% (19)

6% (10)

0.5 (−0.2, 1.1)

0.2 (−0.5, 0.8)

(n=166)

30–44

47.2 (43.1, 53.3)

4.3 (4.1, 4.4)

0.1 (−0.6, 1.0)

−2.3 (−3.4, −1.2)

9% (9)

29% (29)

48% (48)

11% (11)

11% (11)

0.6 (0.0, 1.3)

0.6 (−0.4, 1.4)

(n=99)

15–29
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Average taken from visit immediately prior to first echocardiogram and visit of first echocardiogram

d

c
N=131 (19%) were missing mean heart rate from 24-hr ABPM

eGFRSUN-cr-cys = 39.8 × (height in m/Scr)0.456 × (1.8/Cystatin C)0.418× (30/SUN)0.079 × 1.076 (if male) × (height in m/1.4)0.179

b

eGFRcr = (0.413 × height in cm)/Scr

a

ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; Ca × P, calcium-phosphorus
product; CKD, chronic kidney disease; CKiD, Chronic Kidney Disease in Children; mGFR, measured glomerular filtration rate; eGFR, estimated glomerular filtration rateLVH, left ventriculr hypertrophy;
LVMi, left ventricular mass index; SUN, serum urea nitrogen; Scr, serum creatinine

Note: Values for categorical variables are given as number (percentage); for continuous variables, as median [interquartile range]. Conversion factor for serum creatinine in mg/dL to μmol/L, ×88.4.

42.7 (38.3, 46.9)

4.4 (4.2, 4.6)

Serum Albumin, g/dLd

Ca × P, mg/dLd

0.4 (−0.3, 1.2)

Corticosteroid use

Age-/Sex-specific BMI z scored

7% (47)

Neither visit

−0.8 (−1.9, 0.5)

35% (237)

Both Visits

Race-/Age-/Sex-specific Hemoglobin z scored

8% (57)
51% (346)

Current Visit Only

6% (38)

Prior Visit Only

B-Blocker/ACE inhibitor/ARB use

0.2 (−0.4, 0.9)

Age-/Sex-/Height-specific Systolic BP z scored

(N=678)

≥90

mGFR, mL/min/1.73m2
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---

β-Blocker, ACE inhibitor, ARB useb
---

---

---

---

−10.9, 11.7

−0.8, 0.02

−1.1, 3.1

3.0, 7.0

4.8, 7.9

1.8, 12.1

−5.6, 1.1

−1.2, −0.2

0.7

−1.1

−0.6

−0.05

---

0.3

−2.3

2.9

0.3

−1.3

0.02

−0.7

0.6

−0.1, 1.6

−4.4, 2.3

−1.4, 0.1

−0.2, 0.1

---

−0.01, 0.6

−3.9, −0.7

1.4, 4.5

−0.8, 1.3

−4.7, 2.3

−2.3, 2.4

−1.0, −0.3

−1.1, 2.2

Systolic Function (Shortening
Fraction; n=581; 953 visits)
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---

---

---

---

11.6

0.3

−3.1

0.8

−2.1

5.5

−1.7

0.9

−4.7

---

---

---

---

−1.4, 26.4

−0.2, 0.7

−5.3, −0.8

−1.3, 3.0

−3.6, −0.5

0.1, 11.1

−5.2, 2.1

0.4, 1.5

−7.0, −2.4

E/A Ratio

---

---

---

---

1.1, 31.2

−0.2, 0.8

−8.0, −3.4

−1.9, 2.6

−5.9, −2.6

−7.0, 4.4

−3.0, 5.4

−0.8, 0.4

−9.0, −4.2

---

---

---

---

10.4

−0.1

1.0

2.7

2.9

8.8

3.2

−1.0

2.5

---

---

---

---

−0.9, 23.1

−0.5, 0.4

−1.0, 3.1

0.8, 4.6

1.4, 4.4

3.6, 14.2

−0.3, 6.9

−1.5, −0.5

0.3, 4.7

E/E′ Ratio

Abbreviations and definitions: ABPM – ambulatory blood pressure monitoring; ACE – angiotensin-converting enzyme; ARB – angiotensin II receptor blocker; BMI – body mass index; CKD – chronic
kidney disease; DBP – diastolic blood pressure; LVMi, left ventricular mass index; SBP – systolic blood pressure; SD, standard deviation; E/A ratio (early-to-atrial LV filling ratio), E′/A′ ratio (early-tolate septal mitral annular peak velocity) and E/E′ ratio (estimate of LV filling pressure).

---

---

---

---

15.2

0.3

−5.7

0.3

−4.3

−1.4

1.1

−0.2

−6.6

E′/A′ Ratio

Diastolic Function (n=678; 1,228 visits)

Ordinal valued β-blocker, ACE inhibitor, or ARB use at neither prior nor current visit, prior visit only, current visit only, or both prior and current visits

b

Average taken from previous and current visits

a

Note: Values are given as %change (95% confidence interval). Each analysis is adjusted for the covariates listed in each respective column

---

---

Race-/Age-/Sex-specific Hemoglobin z scorea, per 1SD greater

Serum Albumin, per 1-g/dL greatera

---

Mean Heart Rate from 24-h ABPM, per 1 bpm greater

−0.3

1.0

Age-/Sex-/Height-specific DBP z scorea, per 1-SD
greater

Log(Ca×P)a, mg2/dL2

5.0

Age-/Sex-/Height-specific SBP z scorea, per 1-SD
greater

−0.4

6.4

Length of time with CKD, per 1-y longer

6.9

Age-/Sexspecific BMI z scorea, per 1-SD greater

−2.3

Female sex, vs Male sex

African American, vs non-African American

−0.7

7.7% (5.3% to 10.0%)

Cardiac Structure (LVMi;
n=678; 1,228 visits)

Baseline Age, per 1-y older

Covariates

Cystatin C, per 1-mg/L greater

Exposure

Longitudinal Association of Cystatin C with measures of Cardiac Structure and Function among Children and Adolescents with Mild-Moderate CKD
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Longitudinal Analyses of Correlates of Diastolic Function among Children and Adolescents with MildModerate CKD
E′/A′ Ratio
Model 1: Cystatin C, per 1 mg/L greater

−6.0% (−8.4% to −3.5%)

E/E′ Ratio
2.4

0.2, 4.6

Model 2: eGFRcr b, per 25–mL/min/1.73 m2 decrease

−3.5

−5.9, −1.1

0.6

−1.4, 2.6

Model 3: eGFRSUN-cr-cys c, per 25–mL/min/1.73 m2 decrease

−5.0

−7.6, −2.3

1.6

−0.6, 3.8

Model 4: Serum Creatinined, per 1-mg/dL greater

−3.3

−5.2, −1.4

0.5

−1.1, 2.1

Model 5: mGFR, per 25–mL/min/1.73 m2 decrease

−3.7

−5.8, −1.7

1.9

0.2, 3.6

mGFR, per 25–mL/min/1.73 m2 decrease

−0.9

−3.7, 1.9

1.2

−1.1, 3.5

Cystatin C, per 1-mg/L greater

−5.3

−8.6, −1.8

1.3

−1.6, 4.3

eGFRcr, per 25-–mL/min/1.73 m2 decrease

−0.7

−4.0, 2.6

−1.6

−4.2, 1.1

Cystatin C, per 1-mg/L greater

−6.6

−9.9, −3.1

3.6

0.6, 6.7

Model 6: mGFR + Cystatin C

Author Manuscript

Model 7: eGFRcr + Cystatin C

Note: Values are given as %change (95% confidence interval). Models are adjusted for baseline age, sex, race; length of time with CKD; average of
concurrent and prior age-/sex-specific body mass index z score, log(calcium-phosphorus product), Systolic Blood Pressure z score, Diastolic Blood
Pressure z score

b

eGFRcr = (0.413 × height in cm)/Scr

c

eGFRSUN-cr-cys = 39.8 × (height in m/Scr)0.456 × (1.8/Cystatin C)0.418× (30/SUN)0.079 × 1.076 (if male) × (height in m/1.4)0.179

d
Multivariable model further adjusted for height in cm

Author Manuscript

Abbreviations and definitions: CKD, chronic kidney disease; CKiD – Chronic Kidney Disease in Children study; eGFR – estimated glomerular
filtration rate; mGFR – glomerular filtration rate measured by the plasma disappearance of iohexol. E′/A′ ratio (early-to-late septal mitral annular
peak velocity); E/E′ ratio (estimate of LV filling pressure); SUN, serum urea nitrogen; Scr, serum creatinine
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